Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
F Angriman, BL Ferreyro, L Burry, E Fan… - The lancet respiratory …, 2021 - thelancet.com
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
[HTML][HTML] Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
F Angriman, BL Ferreyro, L Burry, E Fan… - The Lancet …, 2021 - ncbi.nlm.nih.gov
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
F Angriman, BL Ferreyro, L Burry, E Fan… - The Lancet …, 2021 - europepmc.org
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
F Angriman, BL Ferreyro, L Burry, E Fan, ND Ferguson… - 2021 - cabidigitallibrary.org
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
F Angriman, BL Ferreyro, L Burry, E Fan… - The Lancet Respiratory …, 2021 - Elsevier
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
[引用][C] Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
F Angriman, BL Ferreyro, L Burry, E Fan… - The Lancet Respiratory …, 2021 - cir.nii.ac.jp
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[PDF][PDF] COVID-19: Pathophysiology of Acute Disease 3 Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
F Angriman, BL Ferreyro, L Burry, E Fan, ND Ferguson… - Lancet, 2021 - researchgate.net
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context
F Angriman, BL Ferreyro, L Burry… - The Lancet …, 2021 - pubmed.ncbi.nlm.nih.gov
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
F Angriman, BL Ferreyro, L Burry, E Fan… - The Lancet …, 2021 - europepmc.org
The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …
COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 …